TABLE 1.
Demographic and clinical characteristics, and diabetes‐related laboratory values for patients based on data 1 year before index and EOS (year 2019).
| Naïve users | Prevalent users | |||||||
|---|---|---|---|---|---|---|---|---|
| T1D index | T1D 2019 | T2D index | T2D 2019 | T1D index | T1D 2019 | T2D index | T2D 2019 | |
| N | 4016 | 3839 | 47 154 | 38 031 | 30 343 | 27 227 | 63 507 | 37 990 |
| Age, years | 40.8 (16.2) | 44.2 (15.9) | 66.6 (13.6) | 68.4 (13.0) | 45.0 (15.8) | 51.4 (15.1) | 68.5 (11.8) | 72.0 (10.8) |
| Duration of diabetes in years a | N/A | 5.0 (3.6) | 6.6 (5.6) | 10.4 (5.5) | 21.5 (13.2) | 28.8 (12.8) | 11.9 (7.4) | 18.7 (6.8) |
| Male (N, %) | 2430 (60.5) | 2309 (60.1) | 27 300 (57.9) | 22 290 (58.6) | 17 544 (57.8) | 15 558 (57.1) | 35 918 (56.6) | 22 021 (58.0) |
| Follow‐up time, years | ‐ | 4.1 (2.3) | ‐ | 3.8 (2.2) | ‐ | 7.6 (1.4) | ‐ | 6.4 (2.4) |
| Diabetes‐related laboratory values b | ||||||||
| B‐HbA1c, mmol/mol | 102 [76, 125], N 1056 | 60 [49, 71], N 773 | 70 [57, 91], N 7536 | 56 [49, 67], N 5119 | 67 [57, 78], N 5905 | 63 [55, 73], N 5461 | 59 [50, 69], N 8406 | 59 [50, 70], N 5581 |
| fP‐LDL, mmol/L | 2.8 [2.2, 3.5], N 666 | 2.6 [2.1, 3.3], N 620 | 2.4 [1.8, 3.2], N 5330 | 2.2 [1.7, 2.8], N 3728 | 2.4 [1.9, 2.9], N 4716 | 2.3 [1.9, 2.9], N 4495 | 2.2 [1.7, 2.7], N 6727 | 1.9 [1.5, 2.2], N 4256 |
| fP‐trigly, mmol/L | 1.3 [0.9, 2.1], N 688 | 1.0 [0.7, 1.4], N 589 | 1.9 [1.3, 2.7], N 5187 | 1.6 [1.2, 2.4], N 3170 | 1.0 [0.7, 1.4], N 4648 | 1.0 [0.7, 1.4], N 4157 | 1.6 [1.1, 2.2], N 6643 | 1.5 [1.1, 2.2], N 3597 |
| fP‐total‐C, mmol/L | 4.6 [3.8, 5.4], N 671 | 4.5 [3.9, 5.1], N 584 | 4.3 [3.6, 5.3], N 5083 | 3.9 [3.3, 4.7], N 3244 | 4.5 [3.9, 5.1], N 4518 | 4.2 [3.6, 4.9], N 4075 | 4.0 [3.4, 4.8], N 6488 | 3.6 [3.1, 4.3], N 3605 |
| Albumin to creatinine ratio, mg/mmol | 0.8 [0.4, 1.6], 350 | 0.5 [0.4, 1.1], N 555 | 1.4 [0.5, 5.1], N 2552 | 1.4 [0.7, 5.9], N 2475 | 0.3 [0.3, 1.1], N 1608 | 0.82 [0.4, 2.5], N 3840 | 0.76 [0.3, 3.4], N 1570 | 2.3 [0.9, 13.9], N 2806 |
| eGFR | 121 [107, 132], N 1321 | 110 [97, 121], N 1210 | 88 [67, 102], N 10181 | 81 [55, 97], N 11182 | 105 [92, 118], N 4525 | 96 [79, 109], N 8926 | 85 [67, 98], N 8863 | 75 [51, 91], N 12165 |
Note: Data not shown for patients classified as other than T1D or T2D. Values presented as mean (SD) or median [25th, 75th quartile]. Abbreviations: eGFR, estimated glomerular filtration rate; EOS, end of study; fP‐LDL, fasting plasma low‐density lipoprotein; fP‐trigly, fasting plasma triglycerides; HbA1c, hemoglobin A1c; T1D, type 1 diabetes; T2D, type 2 diabetes.
Naïve users: Delay from the initial diagnosis (first date of reimbursement right or diagnosis) to first (index) or last insulin purchase (2019); prevalent users: delay from initial diagnosis (first date of reimbursement right or diagnosis) to January 1, 2012 (index) or last insulin purchase (2019).
n represents number of patients for whom laboratory values were available per test. Closest value within the year before index or EOS reported.